InsightsStrategy & Competition

LEGO was losing one million dollars a day.

By Uttam Dinodia2 min readView this post on LinkedIn

Not because the product failed. Because the strategy did.

By 2003, LEGO carried $800 million in debt and was bleeding cash daily.

The brick still worked. People still loved it.

What broke LEGO was everything it added around the brick: theme parks, clothing, video games, and watches. Each move looked smart on its own. Stacked together, they nearly sank the company.

In 2004, Jorgen Vig Knudstorp made a call most boards would have fired him for: stop expanding. Go back to the brick.

He sold the parks. He cut the product range from 13,000 SKUs to 7,000.

By 2024, LEGO led the global toy industry with roughly $10 billion in revenue.

Here is the part most people miss.

LEGO's collapse was not a diversification problem. It was a sequencing problem.

There is a 1957 framework for this, the Ansoff Matrix. Most people read it as four separate growth options:

  1. Same market, same product (Penetration)
  2. Same market, new product (Product Development)
  3. New market, same product (Market Development)
  4. New market, new product (Diversification)

Risk climbs with every step away from what you already know.

Most leaders treat these four boxes like a menu. Pick the exciting one. Go.

But they are not a menu. They are a staircase.

You earn the right to move outward.

LEGO held a 70% share of the construction toy market when it started buying theme parks. Penetration was still wide open. They skipped the easy wins and jumped straight to the riskiest box.

And the pattern holds at scale. One McKinsey study that followed roughly 1,850 companies over 15 years found that focused players grew faster than diversified conglomerates by a clear margin every year.

The matrix does not tell you which growth move you want.

It tells you which one you have actually earned.

Most growth failures are not bold bets gone wrong. They are good bets made three boxes too early.

Where do you see companies skipping straight to diversification before exhausting the easy wins?

♻️ Repost if this reframes how you read the matrix.

Uttam Dinodia

Uttam Dinodia

Pharmaceutical Business Consultant & Executive Director, A One Afro Limited

Over 22 years in pharmaceutical supply. Helps international manufacturers and Zambian institutions with public tenders, ZAMRA regulatory pathways and distribution.